DK1328289T3 - Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36 - Google Patents

Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36

Info

Publication number
DK1328289T3
DK1328289T3 DK01983562T DK01983562T DK1328289T3 DK 1328289 T3 DK1328289 T3 DK 1328289T3 DK 01983562 T DK01983562 T DK 01983562T DK 01983562 T DK01983562 T DK 01983562T DK 1328289 T3 DK1328289 T3 DK 1328289T3
Authority
DK
Denmark
Prior art keywords
oxidized proteins
biological
well
therapeutic activity
diagnostic use
Prior art date
Application number
DK01983562T
Other languages
English (en)
Inventor
Beate Kehrel
Martin Brodde
Original Assignee
Hamburger Stiftung Zur Foerder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051983A external-priority patent/DE10051983A1/de
Priority claimed from DE2001148624 external-priority patent/DE10148624A1/de
Application filed by Hamburger Stiftung Zur Foerder filed Critical Hamburger Stiftung Zur Foerder
Application granted granted Critical
Publication of DK1328289T3 publication Critical patent/DK1328289T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
DK01983562T 2000-10-20 2001-10-19 Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36 DK1328289T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10051983A DE10051983A1 (de) 2000-10-20 2000-10-20 Inhibierung der pathogenen Wirkung oxidierter Proteine
DE2001148624 DE10148624A1 (de) 2001-10-02 2001-10-02 Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten
PCT/EP2001/012129 WO2002032445A2 (de) 2000-10-20 2001-10-19 Hemmung der interaktion zwischen oxidierte proteine und cd36 oder dessen wirkmechanismus

Publications (1)

Publication Number Publication Date
DK1328289T3 true DK1328289T3 (da) 2008-12-15

Family

ID=26007431

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01983562T DK1328289T3 (da) 2000-10-20 2001-10-19 Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36

Country Status (14)

Country Link
EP (2) EP1328289B1 (da)
JP (1) JP4881535B2 (da)
AP (2) AP2034A (da)
AT (1) ATE406908T1 (da)
AU (1) AU2002215032A1 (da)
CA (1) CA2453140C (da)
CY (1) CY1110418T1 (da)
DE (1) DE50114289D1 (da)
DK (1) DK1328289T3 (da)
ES (1) ES2307662T3 (da)
HK (1) HK1057857A1 (da)
OA (1) OA12431A (da)
PT (1) PT1328289E (da)
WO (1) WO2002032445A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003232209A1 (en) * 2003-04-25 2004-11-23 Hamburger Stiftung Zur Forderung Von Wissenschaft Und Kultur Treatment of hi-virus infections with oxidised blood proteins
US7541340B2 (en) * 2005-09-16 2009-06-02 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
JP2010235447A (ja) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
DE102011003936A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Verwendung von Proteinen/Peptiden, welche an GRP78 (BIP) binden, in Labormethoden zum Monitoring von Thrombozyten-Aggregationshemmern
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (de) * 1988-06-11 1989-12-21 Behringwerke Ag Fibrin(ogen)derivate, verfahren zu ihrer herstellung und ihre verwendung
WO1991004744A1 (en) * 1989-10-06 1991-04-18 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
JPH0780906B2 (ja) * 1990-01-08 1995-08-30 シェリング・コーポレーション Ｇｍ―ｃｓｆの酸化型変異体
JPH05508159A (ja) * 1990-07-18 1993-11-18 ザ　ベス　イスラエル　ホスピタル　アソシエイション 酸化リポプロテインを使用するウイルス感染症の治療方法
WO1995013096A1 (en) 1993-11-08 1995-05-18 Peptide Delivery Systems Pty. Ltd. Labelled diagnostic compositions and methods of their use
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
ATE385575T1 (de) 1997-06-20 2008-02-15 Leuven Res & Dev Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
AU1243500A (en) * 1998-11-06 2000-05-29 Emory University Biomarkers for oxidative stress
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III

Also Published As

Publication number Publication date
ATE406908T1 (de) 2008-09-15
AP2781A (en) 2013-10-31
EP1328289A2 (de) 2003-07-23
ES2307662T3 (es) 2008-12-01
AP2003002795A0 (en) 2003-06-30
AP2009004857A0 (en) 2009-06-30
DE50114289D1 (de) 2008-10-16
AU2002215032A1 (en) 2002-04-29
WO2002032445A2 (de) 2002-04-25
AP2034A (en) 2009-08-28
CY1110418T1 (el) 2015-04-29
EP1328289B1 (de) 2008-09-03
EP1994941A3 (de) 2012-07-25
CA2453140C (en) 2016-01-05
JP2004511526A (ja) 2004-04-15
EP1994941A2 (de) 2008-11-26
JP4881535B2 (ja) 2012-02-22
WO2002032445A3 (de) 2003-04-17
PT1328289E (pt) 2008-12-10
HK1057857A1 (en) 2004-04-23
CA2453140A1 (en) 2002-04-25
OA12431A (en) 2006-04-19

Similar Documents

Publication Publication Date Title
DE60134866D1 (de) Verwendung von imidazochinolinaminen als adjuvantien in dna-impfung
NO20023043L (no) Substituerte oksazolidinoner og deres anvendelse innenfor feltet blodkoagulasjon
ATE355022T1 (de) Chirurgisches system mit griff und kanule
DK1141252T3 (da) Humant delta-5-desaturase-gen samt anvendelser deraf
DK1604679T3 (da) Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte
NO324250B1 (no) Diazabicykliske forbindelser, farmasoytiske sammensetninger omfattende disse samt deres anvendelse
ID26130A (id) Penyempurnaan-penyempurnaan dalam alat pengantar obat
ATE312636T1 (de) Infusion von flüssigkeiten in den menschlichen oder tierischen körper
ID20600A (id) Sel-sel yang dimodifikasi secara genetik dan penggunaannya dalam profilaksis atau terapi penyakit
NO20021964L (no) Biologisk fluidbehandling
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
FI20001715A0 (fi) Rankoihin liittyvät järjestelyt ja menetelmät
NO20001905D0 (no) Forbindelser og deres anvendelse i farmasøytiske eller kosmetiske preparater
NO20013102L (no) Gener, proteiner og deres anvendelse
DK1328289T3 (da) Oxiderede proteiner og deres biologiske og terapuetiske aktivitet samt diagnostisk anvendelse ved hæmning af interaktion mellem oxiderede proteiner og CD36
DE50009838D1 (de) Humanes antibiotisches protein
DE69526203D1 (de) Biologische zielgerichtete mittel
NO20021305D0 (no) DNA-konstruksjon og dens anvendelse
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
GB2349150B (en) Expression of DNA or proteins in C. Elegans
EE200200353A (et) Inimese heparanaasisarnane polüpeptiid ja nukleiinhape
NO20030821D0 (no) Gener og proteiner, og deres anvendelse
ATE256754T1 (de) Gerbstoff-/nachgerbstoffpräparationen
NO20023003D0 (no) Benzofenon-glykopyranosider, samt fremstilling og terapeutisk anvendelse
ES1042932Y (es) Inyector-reactor biologico